We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Hims & Hers Health, Inc. (HIMS) Might be Well Poised for a Surge
Read MoreHide Full Article
Hims & Hers Health, Inc. (HIMS - Free Report) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.
Analysts' growing optimism on the earnings prospects of this company is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- is principally built on this insight.
The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.
For Hims & Hers Health, Inc. Strong agreement among the covering analysts in revising earnings estimates upward has resulted in meaningful improvement in consensus estimates for the next quarter and full year.
Current-Quarter Estimate Revisions
For the current quarter, the company is expected to earn $0.02 per share, which is a change of +140% from the year-ago reported number.
Over the last 30 days, three estimates have moved higher for Hims & Hers Health, Inc. compared to no negative revisions. As a result, the Zacks Consensus Estimate has increased 151.47%.
Current-Year Estimate Revisions
For the full year, the earnings estimate of $0.08 per share represents a change of +172.73% from the year-ago number.
There has been an encouraging trend in estimate revisions for the current year as well. Over the past month, four estimates have moved up for Hims & Hers Health, Inc. versus no negative revisions. This has pushed the consensus estimate 199.5% higher.
Favorable Zacks Rank
Thanks to promising estimate revisions, Hims & Hers Health, Inc. currently carries a Zacks Rank #2 (Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.
Bottom Line
Investors have been betting on Hims & Hers Health, Inc. because of its solid estimate revisions, as evident from the stock's 55.4% gain over the past four weeks. As its earnings growth prospects might push the stock higher, you may consider adding it to your portfolio right away.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Hims & Hers Health, Inc. (HIMS) Might be Well Poised for a Surge
Hims & Hers Health, Inc. (HIMS - Free Report) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.
Analysts' growing optimism on the earnings prospects of this company is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- is principally built on this insight.
The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.
For Hims & Hers Health, Inc. Strong agreement among the covering analysts in revising earnings estimates upward has resulted in meaningful improvement in consensus estimates for the next quarter and full year.
Current-Quarter Estimate Revisions
For the current quarter, the company is expected to earn $0.02 per share, which is a change of +140% from the year-ago reported number.
Over the last 30 days, three estimates have moved higher for Hims & Hers Health, Inc. compared to no negative revisions. As a result, the Zacks Consensus Estimate has increased 151.47%.
Current-Year Estimate Revisions
For the full year, the earnings estimate of $0.08 per share represents a change of +172.73% from the year-ago number.
There has been an encouraging trend in estimate revisions for the current year as well. Over the past month, four estimates have moved up for Hims & Hers Health, Inc. versus no negative revisions. This has pushed the consensus estimate 199.5% higher.
Favorable Zacks Rank
Thanks to promising estimate revisions, Hims & Hers Health, Inc. currently carries a Zacks Rank #2 (Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.
Bottom Line
Investors have been betting on Hims & Hers Health, Inc. because of its solid estimate revisions, as evident from the stock's 55.4% gain over the past four weeks. As its earnings growth prospects might push the stock higher, you may consider adding it to your portfolio right away.